What it is
A phenyl-substituted analog of piracetam developed in Russia. Available as oral tablets where marketed.
How it works
Proposed in preclinical studies to modulate cholinergic, glutamatergic, and dopaminergic neurotransmission, with mild stimulant properties. Exact molecular targets remain incompletely characterized.
Where it's used
Approved in Russia for several neurological indications including stroke recovery. Listed on the WADA prohibited list as a stimulant.
Regulatory status
Not FDA-approved; not marketed in the US.
Tracking it
Phenylpiracetam is oral, which makes consistency the whole game — a simple daily check-off with a reminder beats memory every time. with a half-life of about 4 hours, a dose log also lets a tracker model the relative amount still in your system between doses.
Source
Public reference
Last reviewed 2026-06-11